TibaRay, a Stanford spinout developing next-generation accelerator technology for FLASH radiotherapy, has launched a Regulation CF campaign on Wefunder, opening the company to individual investors. The campaign seeks to fund further development of its proprietary technology, which aims to deliver radiation hundreds of times faster than current systems, potentially reducing damage to healthy tissue while maintaining tumor control.
The company is built on decades of accelerator physics and medical physics research from Stanford University. To date, more than $27 million has been invested in TibaRay's technology, including over $14 million in non-dilutive federal research grants. The company's intellectual property portfolio includes more than 20 issued and pending patents related to next-generation radiotherapy systems.
TibaRay's proprietary Galactica linear accelerator has already been designed into Leo Cancer Care's upright radiotherapy system, marking the company's first commercial integration of its accelerator platform. This partnership underscores the potential of TibaRay's technology to be adapted for various medical and non-medical applications.
The company is pursuing a phased commercialization strategy. In the near term, TibaRay generates revenue by commercializing its accelerator technology across medical and adjacent markets including imaging, security scanning, and non-destructive testing. The long-term objective is the deployment of the PHASER radiotherapy system, designed to enable ultrafast treatment delivery for cancer patients.
FLASH radiotherapy, which involves delivering radiation at ultra-high dose rates, has shown promise in preclinical studies to spare healthy tissues while effectively targeting tumors. However, enabling this type of treatment requires fundamentally new accelerator technology, which TibaRay is developing.
The Wefunder campaign allows individual investors to participate in this next phase of development. Investors can review the full opportunity, including technology details, partnerships, and development plans on the TibaRay campaign page.
This initiative comes as the field of radiation oncology seeks innovative ways to improve treatment outcomes and reduce side effects. By enabling ultrafast radiation delivery, TibaRay's technology could potentially transform cancer care, making treatments faster and more tolerable for patients.
The company's progress is supported by significant non-dilutive funding from federal grants, indicating strong validation from scientific and government bodies. With the Wefunder campaign, TibaRay is now engaging the public to accelerate the development of its technology.
For more information about TibaRay and its technology, visit the original release on NewMediaWire.
